Investor Relations

RSS Content

Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book

WASHINGTON, Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZ® patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.  The '977 patent was issued by the United States Patent and Trademark Office on September 11, 2018 and expires in February 2035.  Prior to this newly listed '977 patent, the HETLIOZ® Orange Book listed patent with the latest expiry date was set to expire in May 2034. 

About Vanda

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit

Company Contact: 
Jim Kelly 
Executive Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc. 
(202) 734-3428


Cision View original content:

SOURCE Vanda Pharmaceuticals Inc.

Home | About Vanda | Product Pipeline| Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2017 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy